Dementia and Storytelling in Vietnam

February 18, 2026 updated by: Hoa Nguyen, University of Massachusetts, Worcester

Digital Storytelling to Promote Early Dementia Diagnosis in Rural Vietnam

This project aims to improve knowledge regarding Alzheimer's dementia and related dementias (ADRD) among older adults and their caregivers in Vietnam and promote the early diagnosis of ADRD using a digital storytelling intervention.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

This study will develop and test a Digital Storytelling intervention to improve older adults' and caregivers' knowledge of ADRD and to facilitate early diagnosis in rural areas of Vietnam. The Digital Storytelling Intervention includes interactive multimedia modules for motivating behavior change and improving knowledge and attitudes toward ADRD among older adults and their caregivers through the power and voices of patients with mild to moderate ADRD, older persons with cognitive concerns, and their caregivers. Mobile Health technology (Computerized Intervention Authoring System - CIAS) will be used to deliver the intervention.

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Older adults (age ≥ 60 years) residing in one of the four participating communities (communities in rural areas of Phu Tho province with minimum distance of 10 km between participating communities)
  • Concern about mild cognitive impairment expressed by the participant, caregiver, or healthcare provider, with no formal screening for ADRD
  • Ability and willingness to provide informed consent
  • Caregivers of eligible participants will be invited to participate after providing written consent.

Exclusion Criteria:

  • Current participation in another ADRD study
  • Severe cognitive impairment as evaluated by study co-investigators
  • Enrollment in palliative care or diagnosis of a terminal illness
  • Previous exposure to digital storytelling modules
  • Prior participation in the digital storytelling development.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control
Participants in this arm will receive basic information.
Behavioral: Basic information
Participants will receive basic information about Alzheimer's disease and related dementias (ADRD), issued by the Vietnam Ministry of Health (usual care), at baseline and at Month 3.
Experimental: Intervention
Participants in this arm will receive the storytelling intervention.
Behavioral: Storytelling intervention
Participants will receive a digital storytelling intervention featuring narratives from older adults with mild to moderate Alzheimer's disease and related dementias (ADRD) and their caregivers who have successfully managed the condition. The stories highlight the benefits of early ADRD diagnosis and strategies for managing diagnostic and care-related challenges. The intervention will be delivered at baseline and biweekly thereafter for three months via CIAS, with didactic "Learn More" modules provided following the stories.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intervention Feasibility: Participant Recruitment and Retention
Time Frame: Baseline, Month 3, Month 6
Feasibility will be assessed using recruitment and retention records, including the number of participants approached, reasons for ineligibility or refusal, and study completion rates.
Baseline, Month 3, Month 6
Intervention Engagement: Interaction Records from CIAS
Time Frame: Month 3, Month 6
Engagement will be assessed using the number of videos watched.
Month 3, Month 6
Intervention Engagement: Exit Interview
Time Frame: Month 6
Information on participants' experiences with the intervention will be collected through exit interviews.
Month 6
Intervention Acceptability: System Usability Scale (SUS)
Time Frame: Month 3, Month 6
SUS is a 10-item, 5-point Likert scale for subjective assessment of usability. The SUS scores range from 0 to 100. A score of > 50 indicates that the technology-based interventions are acceptable.
Month 3, Month 6
ADRD Knowledge: Dementia Knowledge Assessment Scale (DKAS)
Time Frame: Baseline, Month 3, Month 6
DKAS is a 25-item scale that evaluates dementia knowledge. Total scores range from 0 to 50, with higher scores indicating greater knowledge.
Baseline, Month 3, Month 6
Attitudes: Dementia Attitude Scale (DAS)
Time Frame: Baseline, Month 3, Month 6
DAS is a 20-item, 7-point Likert scale assessing attitudes toward dementia and people living with dementia. Items are summed, with selected items reverse-coded as appropriate, to calculate a total score (range: 20-140). Higher scores indicate more positive attitudes.
Baseline, Month 3, Month 6

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ADRD Screening/Diagnosis
Time Frame: Month 3, Month 6
Rates of ADRD screening and diagnosis will be obtained via interviews and through review of participants' medical records by trained study staff. The diagnosis will be reviewed and confirmed by the study co-investigators (physicians).
Month 3, Month 6
Quality of Life: SF-12
Time Frame: Baseline, Month 3, Month 6
The SF-12 is a 12-item scale that assesses health-related quality of life across physical and mental well-being domains. Scores can range from 0 to 100, with higher scores indicating better quality of life.
Baseline, Month 3, Month 6
Self-Care: The Self-Care of Chronic Illness Inventory (SC-CII)
Time Frame: Baseline, Month 3, Month 6
SC-CII is a 29-item scale assessing self-care behaviors across three domains: self-care maintenance, self-care monitoring, and self-care management. Scores range from 0 to 100, with higher scores indicating better self-care.
Baseline, Month 3, Month 6

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Massachusetts, Worcester

Collaborators

Alzheimer's Association

Investigators

  • Principal Investigator: Hoa Nguyen, PhD, University of Massachusetts, Worcester

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 1, 2026

Primary Completion (Estimated)

October 31, 2027

Study Completion (Estimated)

October 31, 2027

Study Registration Dates

First Submitted

February 6, 2026

First Submitted That Met QC Criteria

February 18, 2026

First Posted (Actual)

February 24, 2026

Study Record Updates

Last Update Posted (Actual)

February 24, 2026

Last Update Submitted That Met QC Criteria

February 18, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • STUDY00002680
  • 25HSR-ADRD-1487208 (Other Grant/Funding Number: Alzheimer's Association)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified participant data that will be collected for this study can be obtained by contacting the study PI.

IPD Sharing Time Frame

The final dataset will be available from January 2028 to January 2037.

IPD Sharing Access Criteria

The data and associated documentation will be available to qualified academic investigators for non-commercial research under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; 2) a commitment to securing the data using appropriate computer technology; and 3) a commitment to destroying or returning the data after analyses are completed.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alzheimer Dementia (AD)

Clinical Trials on Basic information

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe